Jun 12, 2016
Do the DANCE #catdancing #goodlaugh #pinksheet #kittydance
Loading...
seen from United States
seen from United States
seen from Russia
seen from Greece
seen from United States
seen from Netherlands
seen from Russia
seen from Germany
seen from United States
seen from United States
seen from United States
seen from United States
seen from United States
seen from United States
seen from United States
seen from Brazil
seen from United States
seen from China
seen from United States
seen from Russia
Do the DANCE #catdancing #goodlaugh #pinksheet #kittydance
Anya is live and ready to show you everything. Watch her strip, dance, and perform exclusive shows just for you. Interact in real-time and make your fantasies come true.
Free to watch • No registration required • HD streaming
Entrepreneurial success partly calls for skill.  Skill is borne from devoutly beating on your craft daily.  Start-up and developing entrepreneurs, especially in the microcap markets, cannot pursue business as a hobby; nor can they say [talk] all day long about what “it will become.” Â
Entrepreneurs, especially those raising money from the public through the micro-cap markets, Pink Sheets or OTCQB/OTCQX, must pursue conquest vehemently, saying not a word… simply showing “what it is or has become” through verifiable action, substantiated by quantifiable results!
Biotechs Have The Power
By Lisa LaMotta
Consulting firm E&Y released its 2015 Beyond Borders report on June 15 from the Biotechnology Industry Organization (BIO) annual meeting in Philadelphia that highlighted the strength of the biotech sector. Not only has the market capitalization for the sector surpassed $1 trillion for the first time, but more than 26 US pre-commercial stage companies have individual market caps greater than $1 billion – up from just three in 2007. The incredible growth in the sector has meant a shift in deal terms as well – biotechs are now able to dictate more favorable terms to their big pharma counterparts. While earn-outs and back-loaded milestone payments were a big part of the deal story during the economic downturn, only 33% of deals during 2014 had an earn-out component – this was down from 45% in 2013. E&Y Global Life Science Leader Glen Giovannetti said in an interview that there are "big premiums" being paid for differentiated assets. "Earn-outs are down, and upfronts and collaborations are up. It's clearly a seller's market," he said. "That's biotech at the bargaining table saying, 'I've got options.'" Currently, money is flowing into the biotech sector and many small companies now have enough capital – through venture rounds and a wide open IPO window – to bring drugs forward without a big pharma partner. For the time being, biotech is in charge.
Our daily BIO 2015 Dispatches draw on the combined forces of “The Pink Sheet” and Scrip Intelligence staff, reporting from the Philadelphia meeting.
From The Pink Sheet. “The Pink Sheet” provides expert, in-depth analysis of biopharma regulatory, legislative, legal and business developments. Find out more at www.ThePinkSheet.com.
From Scrip. SCRIP delivers indispensable news and strategic analysis to the global pharma industry. Find out more at www.scripintelligence.com.
We're recycling approximately 3,000 pounds of pink paper that is usually used for our summer Pink Sheet horse racing insert for the Saratoga Race Course. One roll alone is about 600 pounds.
I'm thinking this could be used for an epic Breast Cancer Awareness project or a cool Halloween costume....
Do lower tier labels (I.E) “Scull & Crossbones” truly effect the liquidity of any given listed company on the OTC Markets?
Michael Slate Slate Asset Group, LLC December 09, 2011
Discussion: (Question) Do lower tier labels (I.E) “Scull & Crossbones” truly effect the liquidity of any given listed company or is it an action by the public companies to boycot the fee structures imposed by the OTC Market?
Over the past few years OTCMarkets.com has been lableing public companies based on disclosure offered by the public companies listed in the varouse markets & the public companies marketing activity. Here is an example of a  Scull & Crossbones labeled company doing exeptional numbers: Symbol: AMWI & check out there chart here
(Question) Should the public company bare the additional OTC Markets cost associated with listing in the top tiers for the promise of better liquidity? Does not seem so in this case, right?
Anya is live and ready to show you everything. Watch her strip, dance, and perform exclusive shows just for you. Interact in real-time and make your fantasies come true.
Free to watch • No registration required • HD streaming
Do lower tier labels (I.E) “Scull & Crossbones” truly effect the liquidity of any given listed company on the OTC Markets?
Michael Slate Slate Asset Group, LLC December 09, 2011
Discussion: (Question) Do lower tier labels (I.E) “Scull & Crossbones” truly effect the liquidity of any given listed company or is it an action by the public companies to boycot the fee structures imposed by the OTC Market?
Over the past few years OTCMarkets.com has been lableing public companies based on disclosure offered by the public companies listed in the varouse markets & the public companies marketing activity. Here is an example of a  Scull & Crossbones labeled company doing exeptional numbers: Symbol: AMWI & check out there chart here
(Question) Should the public company bare the additional OTC Markets cost associated with listing in the top tiers for the promise of better liquidity? Does not seem so in this case, right?
Do lower tier labels (I.E) “Scull & Crossbones” truly effect the liquidity of any given listed company on the OTC Markets?
Michael Slate Slate Asset Group, LLC December 09, 2011
Discussion: (Question) Do lower tier labels (I.E) “Scull & Crossbones” truly effect the liquidity of any given listed company or is it an action by the public companies to boycot the fee structures imposed by the OTC Market?
Over the past few years OTCMarkets.com has been lableing public companies based on disclosure offered by the public companies listed in the varouse markets & the public companies marketing activity. Here is an example of a  Scull & Crossbones labeled company doing exeptional numbers: Symbol: AMWI & check out there chart here
(Question) Should the public company bare the additional OTC Markets cost associated with listing in the top tiers for the promise of better liquidity? Does not seem so in this case, right?
Do lower tier labels (I.E) “Scull & Crossbones” truly effect the liquidity of any given listed company on the OTC Markets?
Michael Slate Slate Asset Group, LLC December 09, 2011
Discussion: (Question) Do lower tier labels (I.E) “Scull & Crossbones” truly effect the liquidity of any given listed company or is it an action by the public companies to boycot the fee structures imposed by the OTC Market?
Over the past few years OTCMarkets.com has been lableing public companies based on disclosure offered by the public companies listed in the varouse markets & the public companies marketing activity. Here is an example of a  Scull & Crossbones labeled company doing exeptional numbers: Symbol: AMWI & check out there chart here
(Question) Should the public company bare the additional OTC Markets cost associated with listing in the top tiers for the promise of better liquidity? Does not seem so in this case, right?